Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rilzabrutinib in Graves' Disease
NCT06984627Phase 2Recruiting
- Sponsor
- Sanofi
- Start
- Sep 2025
- Primary completion
- Feb 2027
- Modality
- Small Molecules
- Countries
- 9
01
Overview
A Phase 2 trial of rilzabrutinib in Graves' disease, sponsored by Sanofi. Started Sep 2025; status: recruiting.
02
Drugs
rilzabrutinib
03
Conditions
Graves' disease
Beyond the preview
Go deeper on NCT06984627.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06984627.